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ABSTRACT
L-asparaginase (L-ASPA) has been put to a wide application in many therapeutic protocols, above all in the
treatment of acute lymphoblastic leukemia (ALL). We presented three cases of acute pancreatitis in children with
ALL induced by administration of L-ASPA preparations. Our observations revealed that ultrasound investigations
are very useful in diagnosis and monitoring changes in the pancreas. The use of L-ASPA derivatives allows to
decrease the toxic and allergic sequele resulting from the administration of the drug.
INTRODUCTION
L-asparaginase (L-ASPA) is an enzyme
(aminohydrolase) obtained from bacterial
strains Escherichia coli or Ervinia carotovora
and Ervinia chrysanthemi. The antineoplastic
mechanism is based on the decomposition of
L-ASPA, the aminoacid required for protein
synthesis and growth of neoplastic cells, into
asparagine acid and ammonia (Opolski, 1981;
Orzechowska-Juzwenko, 1990; Pietras, 1996).
L-ASPA has been put to a wide application in
many therapeutic protocols that are used at
present, above all in the treatment of acute
lymphoblastic leukemia (ALL) and non-
Hodgkin lymphomas (NHL) (Orzechowska-
Juzwenko, 1990; Rokicka-Milewska, 1992).
The use of this drug is restricted to some
extent, however, by its side effects. The most
frequent complication following L-ASPA
obtained from E. coli strain is found to be
abdominal pain and allergic reactions (Clavell,
1986; Rokicka-Milewska, 1992). According to
Rokicka-Milewska, they occur irrespective of
the negative result in the previously performed
allergic test (Rokicka-Milewska, 1992). After
erviniase has been administered, the side
effects are found to occur less frequently and
are limited to allergic reactions of slight
intensity (Rokicka-Milewska, 1992). One of
ma-jor complications following the use of
L-ASPA preparations is acute pancreatitis
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(Chambon, 1993; Clavell, 1986; Filiks-Litwin,
1996; Krasowska, 1987; Niemeyer, 1991 ;
Orzechowska-Juzwenko, 1990; Pietras, 1996;
Rokicka-Milewska, 1992; Taton, 1985). The
incidence of drug-induced pancreas failure
including one induced by L-ASPA, is estimated
at 3-8% (Niemeyer, 1991; Weizman, 1988). It
results from direct toxicity and/or negative
effect of L-ASPA deprivation on the whole
protein metabolism of the organism leading to
a disturbed synthesis of, among others,
albumins, fibrinogens, plasma blotting factors
IX and X, plasminogens, and antithrombin III
(Bradkiewicz, 1995; Oobaczewska, 1998;
Pietras, 1996; Skomra, 1992). Acute
pancreatitis is clinically manifested by
abdominal pains, diarrhoea, vomiting. In order
to establish a diagnosis, it is useful to perform
activity determinations of amylase, lipase and
lactate dehydrogenase (LDH) in blood serum
as well as urine amylase. Moreover, it is also
helpful to determine C-reactive protein (CRP)
concentration in blood serum (Chambon,
1993). Results obtained from imaging
investigations prove to be extremely important.
The ultrasound picture demonstrates most
frequently enlargement and oedema of the
organ, decreased echogenicity, and
sometimes cystoid changes (Chambon, 1993;
Ojala, 1997). In the latter case, a precise
determination of changes is made possible by
the use of computer tomography (CT)
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(Chambon, 1993). Treatment of pancreatitis in
the course of L-ASPA therapy is conservative,
and in selected cases - operative (Balcerska,
1998; Barra, 1990; Chambon, 1993; Filiks-
Litwin, 1996; Ojala, 1997; Rokicka-Milewska,
1992). It should be noted here that there is a
possibility of diabetes, which is caused by
failure of the endocrine part of pancreas
(Balcerska, 1998; Pastore, 1984; Pietras,
1996; Skomra, 1992; Wang, 1993). The issue
Is discussed in a separate report (Stencel,
1998).
The present study is aimed at presenting
cases of pancreas failure in children with
ALL treated with L-ASPA preparations,
demonstrating changes observed in ultrasound
investigations, and indicating those symptoms
which would enable an early identification of
patients with a risk of pancreas failure who
require a rapid intensive therapy.
MATERIALS AND METHODS
Case 1
Rg. 1. Case 1, enlargement of the liver and the pancreas (body - 1,8 cm) with normal echogenicity, free fluid in the peritonea
cavity.
L.W. (case history 5310/97) - an 8-year-old
boy with the common type ALL of the standard
risk group (SRG) with IR=1.6.
Chemotherapy was commenced according to
ALL-BFM 90 trial modified according to Polish
Pediatrics Leukemia/Lymphoma Study Group
(PPLLSG). The drug doses were calculated with
reference to the child's bOdl area (1.0 m2 ):
Prednisone (PSL) - 60mg/m p.o administered
daily in 2 doses, Vincristine (VCR) - 1.5 mg/Fm2
Lv. every 7 days, Daunorubidomycine (DNR) -
16
30 mg/Fm2 Lv. every 7 days, Kidrolase
(L-ASPA) - 10,000 U.m. Um2 Lv. every 2 days.
Initially, the treatment did not cause any
complications. On the 22nd day in the
induction of remission, following the sixth
administration of L-ASPA (total dose - 60,000
u.m.), the patient manifested severe abdominal
pains, loose stools, vomiting. The objective
examination revealed drum belly, tenderness
at palpation in the projection of the stomach,
without peritoneal signs, normal peristaltics.
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Auxiliary investigations showed a low fibrinogen
level (below 50 mg%), increased inflammatory
exponents (CRP - 3.55mg%), high LDH level·
364 u.m.Il, normal amylase levels in blood
serum and urine, normal level of glycemia.
Abdominal ultrasound investigations
demonstrated enlargement within the body of
the pancreas, and features of pancreatitis
(Fig. 1). The dietary treatment was used
together with antibiolicotherapy, fibrinogen's
substitution, Trascolan, symptomatic drugs
(Buscolizyna, Zantac, infusion flUids), which
resulted in improved general state, subsidence
of symptoms, and normalisation of ultrasound
pictures on the 11th day of treatment. Due to
the episode described above, administration of
the remaining two doses of L-ASPA was
discontinued. At present, the patient is in the
first haematological and clinical remission of
leukemia undergoing supportive chemotherapy.
Case 2
Fig. 2. Case 2, enlargement of the pancreas (head - 1,1 em; body - 1,4 em) with increased echogenieity, free fluid in the
peritoneal and pleuraJ cavity.
N.L. (case history 1398/98) - a 7.5-year-old
girl with diagnosed the common type acute
lymphoblastic leukemia, which belonged to the
standard risk group with IR=1.22. Induction of
remission was commenced according to ALL-
BMF 90 Protocol. Doses of drugs (Prednisone,
Vincristine, Daunorubidomycine) were
established calculating the patient's body area
1.0m2 Moreover, an oral prevention of
infections was used (Nystatyna, Biseptol,
Colistin). On the 19th day of induction (I.e.
following the third dose of Kidrolaze - total
dose 30,000u.m.), the patient manifested
abdominal pains and loose stools. The
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objective examination revealed soft abdomen,
tenderness at palpation in the projection of the
stomach, lack of peritoneal symptoms, normal
peristaltics. Auxiliary investigations showed
increased levels of glycemia (125-170 mg%),
high inflammatory exponents (CRP • 4.22
mg%), LDH - 893 u.m.ll, leukopenia (200 G/I),
hypofibrinogenemia (below 56 mg%),
hypoproteinemia (3.97 g%), hyperuricemia
(14.8 mg%), and increased levels of urea (83
mg%). There were no increased levels of
amylase in blood serum and urine. The
ultrasound investigation revealed the enlarged
hyperechogenic pancreas with the following
17
Oerwlch et al.: Pancreas failure during L~asp ...
dimensions: head - 18 mm, body - 12 mm, tail -
14 mm without widening of the Wirsung duct,
and with homogenous parenchyma, significant
quantity of free fluid in the peritoneal cavity,
and enlarged kidneys of intensified cortex
echogenicity and increased cortico-spinal
differentiation. (Fig.2). Intensive dietary therapy
was used in association with antibioticotherapy
(Cefotaksym, Dalacin, Vancocin, Diflucan),
blood derivatives (CPAG, plasma, albumins,
Bioglobuiin), symptomatic drugs, and infusion
fluids, which, on the 16th day of treatment,
resulted in improved clinical state,
normalisation of laboratory and imaging
resuits. The chemotherapy was continued
replacing Kidrolaze with Erviniase. The
treatment continued without any complications.
Case 3
Fig. 3. Case 3, the hyperechogenic, enlarged pancreas (body, tail - 2,5 - 2,7 cm), blurred outline of the anterior capsule
homogenous pancreatic parenchyma, free fluid in the peritoneal cavity.
K.B. (case history· 4205/98) a 10-year-old
boy with infantile cerebral palsy. T-cell acute
lymphoblastic leukemia was diagnosed,
belonging to the high risk group. The induction
of remission was commenced according to
New York Protocol. Five days after the first
administration of VCR, the patient manifested
severe abdominal pain. In the objective
examination, drum belly with diffuse
tenderness at palpation, and hypoperistaltics
without peritoneal symptoms were observed.
Radiological investigations revealed faecal
impaction, and symptoms of low obstruction.
The above mentioned symptoms subsided
after a single administration of prokinetic drugs
(Ubretid). On the 5th day after the first
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administration of Kidrolaze according to
remission consolidation (dose of 30,000 u.m.,
total dose of four Kidrolaza administrations -
120 thousand u.m.), the patient manifested
severe abdominal pain. At admission to the
Clinic, the patient had a serious general state.
The severe pains were accompanied by
paleness of skin inguments, hypotension,
tachycardia, filiform pulse. The objective
examination revealed diffuse abdominal
tenderness was accompanied by
hypoperistaltics without observed peritoneal
symptoms.
In the auxiliary investigations, the follo-
wing results were obtained: serum diastase
- 524.8 U/i, plasma lipase - 2153 U/I urine
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diastase - 3753 U/I, CRP - 3.7 mg%, glucose -
318 mg%, Hb -12.1 g%, leukocytes -12.0 GIl,
thrombocytes 520 GIl. The USG
investigations revealed features of acute
pancreatitis (Fig. 3). The therapeutic treatment
included a stomach tube, Sandostatin 0.05mg
- three times daily subcutaneously, Trascolan -
4 x 100 thousand u., analgesics (Tramal,
Pyralgin), anti-infectious drugs (Fortum,
Metronidazol, Sandoglobulin). In view of the
suspected onset of intravascular clotting
(decreased number of thrombocytes, positive
paracoagulation tests, increased FOP), the
therapy included also heparin in the dose of
4 x 1000 u. In order to obtain normal diuresis
at pertinent blood pressure of 70/40,
4ug/kg/min dopamine was included. Complete
parenteral nutrition was used (glucose drip
infusion contained insulin due to
hyperglycemia). After a 24-hour period, there
was already a considerable improvement of
the clinical state (diminished pain sensation,
normalised blood pressure, DlC was
excluded). After seven days, the diastin level
was found to reach a normal range,
Sandostatin and Trascolan administration were
discontinued. Due to the described reaction,
administration of further doses of Kidrolaze
was discontinued. The patient continued
chemotherapy.
DISCUSSION
Despite the increasingly more positive results
even in the highest risk groups, treatment of
acute lymphoblastic leukemia is still found to
cause many problems. The intensity of
antileukemic therapy proves to be causing
occurrence of a series of complications which,
by themselves, constitute a danger to the
child's health and life. One of the complications
induced by the administration of cytostatic
drugs is acute pancreatitis (AP). This rare
disease in the population of children and
adolescents (10-15/100 000) (Barra, 1990) is
found to occur as a drug-induced complication
in 3-8% patients (Niemeyer, 1991; Weizman,
1988) whereas among those receiving
L-asparaginase preparations - in 2-2.5% (Filiks
-Litwin, 1996).
In the reported three cases, AP was induced
by administration of L-asparaginase
preparations, and was characterised by some
common features. The onset of the first
symptoms occurred on the 22nd, 19th and
33rd day of the therapy following the 6th, 3rd
and 4th dose of the drug, respectively (total
doses: 60000 , 30000 and 120 000 u.m.,
respectively). It is in agreement with reports of
other authors observing occurrence of AP
following L-asparaginase between the 2nd day
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and 10th week from the administration of the
drug (Filiks-Litwin, 1996). The patients
reported typical complaints, predominant
abdominal pains of various intensity were
found in all the cases. In 2 patients, loose
stools were reported and in 1 patient,
additionally vomiting.
The objective examination revealed
tenderness at palpation in the projection of the
stomach without peritoneal symptoms or
disorders of peristaltic movement. Only in one
case (patient K.B.), the course of the disease
was more intensive with observed
hypoperistaltics and traumatic symptoms in the
form of tachycardia and decreased arterial
blood pressure. Disorders of peristaltics, and
metoerism previously observed in the patient,
are associated with intravenous administration
of vincristine (VCR). The subjective and
objective changes observed in our patients did
not differ from those reported by other authors
(Balcerska, 1998; Barra, 1990; Bukowska,
1995, Chambon, 1993; Pietras, 1996; Rokicka-
Milewska, 1992, Weizman, 1988).
Results of the auxiliary investigations
demonstrated in all the patients slightly
increased CRP values (3.55 - 4.22 mg%), in 2
cases - decreased fibrinogen levels and
hyperglycemia, in 1 case requiring the
intravenous administration of insulin. Since in
patient K.B., features of intravascular clotting
were observed, heparin was administered. It
should be noted that there were no changes in
serum and urine amylase levels in 2 patients.
Only in 1 patient, the amylase level exceeded
the levels indicating AP Le. >500U/I in serum,
and >2300 U/I in urine (Barra, 1990) (524.8 and
3753 U/I respectively). It concerned the patient
with the most serious course of the disease
following the administration of the largest dose
of L-asparaginase. According to the data
obtained from the literature, in 1/3 patients with
AP there is no increase of amylase serum or
urine activity (Barra, 1990), and the presented
cases are found to confirm the observation
(although there was no possibility to carry out
statistical analysis). Clavell describes the so
called transient hyperamylasemia syndrome
which is a laboratory equivalent of AP. It is a
transient (48-72 hours) increase of blood serum
amylase levels ( less than a 10-time or usually
even less than a twofold increase) with no
evident exponents of pancreas failure (Clavell,
1986). It can be inferred that in the course of
differentiation of the causes of abdominal pains
in the child with neoplastic disease, obtaining
normal serum and amylase levels is found not
to exclude unambiguously the occurrence of AP
whereas the increased levels are not
pathogenic. It makes it necessary to seek other
19
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methods useful in diagnosing and
differentiating AP. It seems that abdominal
ultrasonography may turn out to be such an
investigation.
In our patients, the most frequently observed
changes in the ultrasound investigation were
enlargement of the pancreas and changes in
its echogenicity (both an decrease as well as
an increase) and presence of the free fluid in
the peritoneal cavity. It should be emphasised
that the ultrasound picture in AP is not
homogeneous. The character and intensity
of the changes depend on the clinical form
and progression of AP (Table 1). Correct inter-
pretation of the ultrasound image is therefore
possible only in connection to the clinical
picture, results of auxiliary investigations and in
reference to specially prepared population
norms (Table 2, Table 3). In view of the
described possibility of a lack of changes in
amylase activity, the ultrasound investigation
becomes extremely useful in early detection
and differentiation of AP with cholelithiasis
and inflammation in the billiary system,
nephrolithiasis and other acute abdominal
diseases, and when it is performed serially, it
also proves to be a very significant element of
monitoring the course of the disease.
1. Homogenous echostructure typical of organs with parenchymal structure.
2. Echogenicity depending on child's age and amount of fatty tissue in the stroma up to
10 years of age usually not bigger than the echogenicity of the liver.
3. Smooth edges, sharp separation from environment.
4. The Wirsung duct invisible or visible only within the body width up to 2 mm.
Table 1. Picture of normal pancreas in the ultrasound investigation.
Age Pancreas dimensions
head body tail
0-6 years 1.6 0.7 1.2
7-12 years 1.9 0.9 1.4
13-18 years 2.0 1.0 1.6
AP 2.2-4.0 0.8-2.0 1.4-3.5
Table 2. Normal dimensions of the pancreas in children (em) according to Coleman (7).
1. Focal or diffuse enlargement of the pancreas.
2. Decreased echogenicity of pancreatic parenchyma reflecting oedema, rarely increased
echogenictity as a symptom of necrosis.
3. Sometimes widening of the Wirsung duct.
4. False cysts.
5. Free fluid in the peritoneal cavity sometimes in the left pleural cavity.
Table 3. Diagnostic criteria for acute pancreatitis in the ultrasound investigation.
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Treatment of our patients included complete
parenteral nutrition, which was linked to
insertion of a stomach tube in 1 case,
antibiotics and symptomatic drugs. In the most
serious case, it was necessary to administer
Sandostatin, Dopamine, Heparin and Insulin.
The therapy lasted 11, 16, and 7 days,
respectively. In all the cases, we achieved
restitution, subsidence of clinical symptoms
and deviations in the objective state,
normalisation of laboratory results, and normal
ultrasound pictures of the pancreas. In 1
patient, after the administration of two
consecutive doses of L-asparaginase was
given up, the chemotherapy with Kidrolaze
was continued, in 1 - Erviniase was introduced
interchangeably, and in KoB. who manifested
the most intensive course of AP, further
administration of L-asparaginase preparations
was discontinued. Other authors also point to
the fact that there is a possibility of a complete
subsidence of AP without complications
following a conservative treatment, and thus
enabling continuation of the antileukemic
therapy (Balcerska, 1998; Barra, 1990;
Chambon, 1993; Filiks-Litwin, 1996; Rokicka-
Milewska, 1992). In order to avoid or decrease
the toxic or allergic complications induced by
the administration of L-asparaginase
preparations, new derivatives of these drugs
are now being developed. An example could
be a combination of L-asparaginase with
polyethylene glycol (Oncaspar) which so far
has been administered in a small group of
patients and has yielded good results
(Sikorska-Fic, 1998).
CONCLUSIONS
1. In the diagnosis and differentiation of
causes of abdominal pains in patients with
neoplastic diseases, particularly in the
course of the therapy with L-asparaginase
preparations, it is necessary to include
pancreatitis.
2. In the course of AP, changes in the blood
serum and urine amylase activity may turn
out to be small or may not occur at all.
3. Ultrasound investigations prove to be very
useful in diagnosis and monitoring of
changes in the pancreas.
4. The Ultrasound picture is heterogeneous
according to the variety of clinical forms and
clinical progression of AP.
5. The role of the ultrasound investigation
includes also early detection of
complications, and differentiation with
cholelithiasis and inflammation in the biliary
system, nephrolithiasis and other acute
diseases in the abdominal cavity.
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6. In the majority of cases, early
commencement of appropriate conservative
therapy allows to obtain complete
subsidence of changes and thus to
continue the therapy.
7. The use of Erviniase-derived preparations
as well as L-asparaginase derivatives
allows to decrease the toxic and allergic
sequele resulting from the administration of
the drug.
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